Figure 1 Proposed risk stratification for patients with NAFLD

Slides:

Advertisements

Similar presentations

Measurement of liver fibrosis Amar Dhillon Royal Free and University College Medical School.

Advertisements

Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD Featured Article: Jessica Bazick,

Simple Noninvasive Systems Predict long-term Outcome of Patients With NAFLD Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera.

Nonalcoholic Fatty Liver Disease / Nonalcoholic Steatohepatitis 소화기내과 R3 신아리 1.

Interpreting Your Test Results

NAFLD and NASH: The Not-So-New Kids on the Block

Metabolism - Clinical and Experimental

Supplementary Table 1. Dissociation cases of EI and Fibrosis Case 1 2

Volume 133, Issue 2, Pages (August 2007)

Figure 4 Activation of clopidogrel via cytochrome P450

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 A stage-based approach to the treatment of NAFLD

Figure 7 Management algorithm for patients with ACLF

Figure 5 Lipid droplet consumption

Figure 3 Semantic model of the active surveillance (AS) timeline

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Non-invasive diagnosis of non-alcoholic fatty liver disease

Figure 1 Biosimilar development process

Figure 5 Risk factor control in the intensive treatment group

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Proposed algorithm for the management

Figure 4 Giant lipid droplet formation

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Suggested biopsy-avoiding diagnostic pathway for coeliac disease Figure 1 | Suggested biopsy-avoiding diagnostic pathway for coeliac disease.

Volume 145, Issue 4, Pages e4 (October 2013)

Figure 4 Effects of irisin on glucose homeostasis

Figure 1 Definition and concept of ACLF

Nat. Rev. Nephrol. doi: /nrneph

Figure 2 Switching of biologic agents and biosimilars

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Prevalence of NAFLD (panel A) and advanced fibrosis (panel B) in the general population and in patients with T2DM according to different diagnostic tools.

to the liver and promote patient-derived xenograft tumour growth

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Environmental factors contributing to IBD pathogenesis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Clinical algorithms in the management of NASH and diabetes mellitus Figure 3 | Clinical algorithms in the management of NASH and diabetes mellitus.

Figure 2 13C-octanoic acid gastric emptying breath test

Figure 4 Functional luminal imaging probe

in the UK (1961–2012), France (1961–2014) and Italy (1961–2010)

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Possible therapeutic targets to decrease hepatic steatosis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Strategies to improve liver regeneration

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Chan Wah Kheong, Nik Raihan Nik Mustapha, Sanjiv Mahadeva

Figure 5 PPIs and adverse events with proven and unproven causality

Volume 133, Issue 2, Pages (August 2007)

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Serum Activity of Macrophage-Derived Adenosine Deaminase 2 Is Associated With Liver Fibrosis in Nonalcoholic Fatty Liver Disease Z. Gordon Jiang, Bynvant.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Lifelong influences on the gut microbiome from

Figure 1 NAFLD pathogenesis

Non-invasive evaluation of liver fibrosis using transient elastography

Volume 64, Issue 6, Pages (June 2016)

Volume 140, Issue 1, Pages (January 2011)

Volume 142, Issue 6, Pages e4 (May 2012)

Laurent Castera, Mireen Friedrich-Rust, Rohit Loomba Gastroenterology

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Response to abnormal liver blood tests.

NAFLD and NASH in Europe and Canada

Validation of serological biomarkers for detection of non-alcoholic fatty liver disease (NAFLD) and/or advanced liver fibrosis in people living with HIV.

Presentation transcript:

Figure 1 Proposed risk stratification for patients with NAFLD Figure 1 | Proposed risk stratification for patients with NAFLD. After suspected NAFLD has been confirmed, patients can be stratified by their risk of NAFLD progression, on the basis of their noninvasive risk factor profiles. If noninvasive risk factors cannot definitively determine risk profile, liver biopsy can be used to aid stratification. Presence of MELD >10 or HVPG >10 mmHg is associated with development of adverse clinical outcomes within 1–2 years in 20% of patients. *High-quality data for the use of Fibroscan® (Echosens, France) in patients with NASH are emerging and require confirmation. ‡Cut-off values reported by Angulo et al.118. ALT, alanine aminotransferase; APRI, aspartate aminotransferase to platelet ratio index; FIB-4, fibrosis-4 index; HVPG, hepatic venous pressure gradient; MELD, model for end-stage liver disease; NFS, NAFLD fibrosis score; T2DM, type 2 diabetes mellitus. Rinella, M. E. & Sanyal, A. J. (2016) Management of NAFLD: a stage-based approach Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2016.3